Oncology Learning Network CME- Emerging Treatm... - CLL Support

CLL Support

22,532 members38,709 posts

Oncology Learning Network CME- Emerging Treatments for CLL / SLL included in NCCN and ESMO guidelines

lankisterguy profile image
lankisterguyVolunteer
0 Replies

This video and most on the Oncology Learning Network CME are intended for trained medical professionals, but those comfortable with MedSpeak can sign up for an account to view this excellent presentation by Dr. Nicole Lamanna of Columbia NY Presbyterian

here: hmpeducation.com/content/ac...

This accredited, on-demand activity features a presentation that discusses the genetic characteristics of CLL/SLL, including 17p deletions, and how gene mutation status affects patient outcomes in response to targeted therapies.

INTENDED LEARNERS

This activity is designed to meet the educational needs of U.S. hematologists, medical oncologists, and other health-care professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants, etc) who are involved and/or interested in the treatment of patients with multiple myeloma, lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms.

LEARNING OBJECTIVES

After participating in this activity, learners should be better able to:

Explain the genetic characteristics of CLL/SLL, including 17p deletions, and how gene mutation status affects patient outcomes in response to targeted therapies

Evaluate the mechanism of action, safety/efficacy data, and potential drug-drug interactions associated with major emerging agents, including Anti CD-20 mABs, BCL-2 inhibitors, and BTK inhibitors

Incorporate guideline recommendations for cytogenetic analysis and minimal residual disease (MRD) monitoring into the care of patients with CLL/SLL

ACTIVITY OVERVIEW

This on-demand webcast is available with synchronized slides and audio.

To be eligible for credit, participants must complete the educational activity, complete the X-question post-test with a score of 70% or better, and complete the evaluation form. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

Release Date: August 23, 2022

Expiration Date: August 22, 2023

Estimated Time to Complete: 2.25 hour

There is no fee associated with this activity.

-

Len

Written by
lankisterguy profile image
lankisterguy
Volunteer
To view profiles and participate in discussions please or .
Read more about...

You may also like...

Looking for a resource re treatment for CLL/SLL

exists that outlines clearly \\"if this is your CLL/SLL genetic profile, these are your specific...

Potential Early Drivers of Disease in Treatment-Naive CLL Identified

prognostic factors and 29 gene mutations in patients with TN CLL, mutated ATM and unmutated IGHV...